48 Ranolazine PPTs View free & download

Ranolazine: Long-term use PowerPoint PPT Presentation

Ranolazine: Long-term use - QTc 500msec: 10 patients; Torsade de Pointes: 0 patients. Ranolazine discontinuation due ... Age 64 years and prior Hx of HF were significant predictors. of ...

QTc 500msec: 10 patients; Torsade de Pointes: 0 patients. Ranolazine discontinuation due ... Age 64 years and prior Hx of HF were significant predictors. of ...

| PowerPoint PPT presentation | free to view

Ranolazine: Pathophysiologic effects vs older antianginals PowerPoint PPT Presentation

Ranolazine: Pathophysiologic effects vs older antianginals - Ranolazine: Pathophysiologic effects vs older antianginals ... Non-DHP CCBs. DHP CCBs. -blockers. Myocardial contractility. Venous return. Arterial pressure ...

Ranolazine: Pathophysiologic effects vs older antianginals ... Non-DHP CCBs. DHP CCBs. -blockers. Myocardial contractility. Venous return. Arterial pressure ...

| PowerPoint PPT presentation | free to view

Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization PowerPoint PPT Presentation

Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization - Increase in QTc Interval, msec. Incidence of TdP, % A better surrogate of pro-arrhythmic potential is needed. ... Endocardium. LV chamber ...

Increase in QTc Interval, msec. Incidence of TdP, % A better surrogate of pro-arrhythmic potential is needed. ... Endocardium. LV chamber ...

| PowerPoint PPT presentation | free to view

Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization - Ranolazine reverses APD (and QT) prolongation, suppresses EADs and ventricular tachycardia (VT) caused by Ranolazine suppresses EADs induced by: quinidine, ...

Ranolazine reverses APD (and QT) prolongation, suppresses EADs and ventricular tachycardia (VT) caused by Ranolazine suppresses EADs induced by: quinidine, ...

| PowerPoint PPT presentation | free to download

The Late Sodium Current in the cardiac myocite: How viable as a new therapeutic target in angina? PowerPoint PPT Presentation

The Late Sodium Current in the cardiac myocite: How viable as a new therapeutic target in angina? - Ranolazine Perhexiline - Trimetazidine Are there any other options? Mechanisms of Drug Action Reduce Heart Rate -Blockers, Verapamil/Diltiazem, ...

Ranolazine Perhexiline - Trimetazidine Are there any other options? Mechanisms of Drug Action Reduce Heart Rate -Blockers, Verapamil/Diltiazem, ...

| PowerPoint PPT presentation | free to view

Ranexa Supportive Slides PowerPoint PPT Presentation

Ranexa Supportive Slides - Exercise Performance in Males vs Females Ranolazine IR vs Atenolol. RAN080. 23 ... Atenolol 100 mg qd. Duration of exercise, sec. Female. Male. Variable ...

Exercise Performance in Males vs Females Ranolazine IR vs Atenolol. RAN080. 23 ... Atenolol 100 mg qd. Duration of exercise, sec. Female. Male. Variable ...

| PowerPoint PPT presentation | free to view

Prise en charge du syndrome coronarien aigu chez le patient non choqu PowerPoint PPT Presentation

Prise en charge du syndrome coronarien aigu chez le patient non choqu - Autres th rapeutiques : Ivabradine, Trimetazidine, Ranolazine, Nicorandil : peu de donn es. Traitement anticoagulant (1) H parine non fractionn e : ...

Autres th rapeutiques : Ivabradine, Trimetazidine, Ranolazine, Nicorandil : peu de donn es. Traitement anticoagulant (1) H parine non fractionn e : ...

| PowerPoint PPT presentation | free to view

Cattedra di Cardiologia,Universit PowerPoint PPT Presentation

Cattedra di Cardiologia,Universit - Cattedra di Cardiologia,Universit di Napoli Federico II

Cattedra di Cardiologia,Universit di Napoli Federico II

| PowerPoint PPT presentation | free to view

New Therapeutic Options for Chronic Stable Angina PowerPoint PPT Presentation

New Therapeutic Options for Chronic Stable Angina - Sulfi S, Timmis AD. Ivabradine the first selective sinus node If channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006;60:222-228.

Sulfi S, Timmis AD. Ivabradine the first selective sinus node If channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006;60:222-228.

| PowerPoint PPT presentation | free to view

New Therapeutic Options for Chronic Stable Angina - International Trial on the Treatment of Angina with Ivabradine vs. Atenolol ... Ivabradine 7.5 mg bid and 10 mg bid were noninferior to atenolol 100 mg as measured by ...

International Trial on the Treatment of Angina with Ivabradine vs. Atenolol ... Ivabradine 7.5 mg bid and 10 mg bid were noninferior to atenolol 100 mg as measured by ...

| PowerPoint PPT presentation | free to view

Ranexa - Jeremy Ruskin, MD, FACC. Massachusetts General Hospital. Benefit/Risk ... St. George's Hospital Medical School London, England. Marek Malik, MD, PhD, FACC ...

Jeremy Ruskin, MD, FACC. Massachusetts General Hospital. Benefit/Risk ... St. George's Hospital Medical School London, England. Marek Malik, MD, PhD, FACC ...

| PowerPoint PPT presentation | free to view

Contemporary Management of Myocardial Ischemia PowerPoint PPT Presentation

Contemporary Management of Myocardial Ischemia - Growing prevalence of chronic ischemia (angina) due to residual CAD after PCI and CABG ... QTc 500msec: 10 patients; Torsade de Pointes: 0 patients ...

Growing prevalence of chronic ischemia (angina) due to residual CAD after PCI and CABG ... QTc 500msec: 10 patients; Torsade de Pointes: 0 patients ...

| PowerPoint PPT presentation | free to view

Myocardial Ischemia Update PowerPoint PPT Presentation

Myocardial Ischemia Update - Myocardial Ischemia Update * While chronic ischemic heart disease continues to pose a major clinical challenge, advances have been made in understanding both the ...

Myocardial Ischemia Update * While chronic ischemic heart disease continues to pose a major clinical challenge, advances have been made in understanding both the ...

| PowerPoint PPT presentation | free to download

Personalized Medicine: Applying Guidelines to the Individual Patient With SIHD PowerPoint PPT Presentation

Personalized Medicine: Applying Guidelines to the Individual Patient With SIHD - Personalized Medicine: Applying Guidelines to the Individual Patient With SIHD SIHD Guidelines Case 1: Patient With No Known CAD Getting a Good History SIHD ...

Personalized Medicine: Applying Guidelines to the Individual Patient With SIHD SIHD Guidelines Case 1: Patient With No Known CAD Getting a Good History SIHD ...

| PowerPoint PPT presentation | free to download

Redefining Treatment Strategies for Optimal Medical Care in CAD PowerPoint PPT Presentation

Redefining Treatment Strategies for Optimal Medical Care in CAD - Redefining Treatment Strategies for Optimal Medical Care in CAD COURAGE and MERLIN-TIMI 36 COURAGE Clinical Outcomes Utilizing Revascularization and Aggressive Drug ...

Redefining Treatment Strategies for Optimal Medical Care in CAD COURAGE and MERLIN-TIMI 36 COURAGE Clinical Outcomes Utilizing Revascularization and Aggressive Drug ...

| PowerPoint PPT presentation | free to view

ACTIVE PHARMACEUTICAL INGREDIENTS FROM DEV LIFE CORPORATION PowerPoint PPT Presentation

ACTIVE PHARMACEUTICAL INGREDIENTS FROM DEV LIFE CORPORATION - ... asthmatic / bronchodilator montelukast sodium roflumilast salmeterol xinafoate zafirlukast anti hypertensive eplerenone ... powerpoint presentation ...

... asthmatic / bronchodilator montelukast sodium roflumilast salmeterol xinafoate zafirlukast anti hypertensive eplerenone ... powerpoint presentation ...

| PowerPoint PPT presentation | free to download

The Obesity/Diabetes Epidemic: Adiposopathy PowerPoint PPT Presentation

The Obesity/Diabetes Epidemic: Adiposopathy - Title: Obesity Rates Are Projected to Double Over the Next 30 Years Author: Rebecca Rothman Last modified by: Heather McConnell Created Date: 2/6/2002 7:04:36 PM

Title: Obesity Rates Are Projected to Double Over the Next 30 Years Author: Rebecca Rothman Last modified by: Heather McConnell Created Date: 2/6/2002 7:04:36 PM

| PowerPoint PPT presentation | free to download

Ongoing Trials in Managing Myocardial Ischemia - Ongoing Trials in Managing Myocardial Ischemia

Ongoing Trials in Managing Myocardial Ischemia

| PowerPoint PPT presentation | free to view

Examining the Science Underlying Myocardial Ischemia PowerPoint PPT Presentation

Examining the Science Underlying Myocardial Ischemia - VPC = ventricular premature contraction VT = ventricular tachycardia Risk factors Age Heredity Gender Smoking Lipids Hypertension Diabetes Obesity Clinical or ...

VPC = ventricular premature contraction VT = ventricular tachycardia Risk factors Age Heredity Gender Smoking Lipids Hypertension Diabetes Obesity Clinical or ...

| PowerPoint PPT presentation | free to view

Coronary Heart Disease Market Size, Share, Demand, Report, Forecast 2024-2032 PowerPoint PPT Presentation

Coronary Heart Disease Market Size, Share, Demand, Report, Forecast 2024-2032 - The 7 major coronary heart disease markets are expected to exhibit a CAGR of 5.17% during 2024-2034.

The 7 major coronary heart disease markets are expected to exhibit a CAGR of 5.17% during 2024-2034.

| PowerPoint PPT presentation | free to download

$Heart failure with preserved ejection fractio PowerPoint PPT Presentation$

Heart failure with preserved ejection fractio - Heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction

| PowerPoint PPT presentation | free to download

Practical Considerations in Chronic Ischemic Heart Disease Management PowerPoint PPT Presentation

Practical Considerations in Chronic Ischemic Heart Disease Management - Reduce ischemia and relieve anginal symptoms. Improve quality of life ... Many patients are not ... Shaw LJ et al. J Am Coll Cardiol. 1999;33:661-9. ...

Reduce ischemia and relieve anginal symptoms. Improve quality of life ... Many patients are not ... Shaw LJ et al. J Am Coll Cardiol. 1999;33:661-9. ...

| PowerPoint PPT presentation | free to view

Supplementary Table 1. PowerPoint PPT Presentation

Supplementary Table 1. - Supplementary Table 1. Selected reference drugs, testing concentrations and therapeutic exposure a Ceff, the maximal therapeutic plasma concentration reported in the ...

Supplementary Table 1. Selected reference drugs, testing concentrations and therapeutic exposure a Ceff, the maximal therapeutic plasma concentration reported in the ...

| PowerPoint PPT presentation | free to download

Ischemic Heart Disease Chapter 17 PowerPoint PPT Presentation

Ischemic Heart Disease Chapter 17 - Etiology/Pathophysiology. Determinants of myocardial oxygen demand (MVO2) HR. contractility ... ventricular diastolic pressure, with or without clinical CHF ...

Etiology/Pathophysiology. Determinants of myocardial oxygen demand (MVO2) HR. contractility ... ventricular diastolic pressure, with or without clinical CHF ...

| PowerPoint PPT presentation | free to view

Ischemic Heart Disease Chapter 17 - Pharmacotherapy: A Pathophysiologic Approach The McGraw-Hill Companies Table Footnotes aRefers to all patients diagnosed with CAD bMedical reasons for not prescribing ...

Pharmacotherapy: A Pathophysiologic Approach The McGraw-Hill Companies Table Footnotes aRefers to all patients diagnosed with CAD bMedical reasons for not prescribing ...

| PowerPoint PPT presentation | free to download

Examining the Science Underlying Myocardial Ischemia - Courtesy of PH Stone, MD. Major cardiac events occur in non-target areas ... Disease(s) and pathological states linked to imbalance. of O2 supply/demand ...

Courtesy of PH Stone, MD. Major cardiac events occur in non-target areas ... Disease(s) and pathological states linked to imbalance. of O2 supply/demand ...

| PowerPoint PPT presentation | free to view

Myocardial infarction with non-obstructive coronary arteries - Myocardial infarction with non-obstructive coronary arteries

Myocardial infarction with non-obstructive coronary arteries

| PowerPoint PPT presentation | free to download

Arshed A. Quyyumi MD PowerPoint PPT Presentation

Arshed A. Quyyumi MD - Current management of stable coronary artery disease Atlanta Arshed A. Quyyumi MD Professor of Medicine Division of Cardiology Emory University School of Medicine

Current management of stable coronary artery disease Atlanta Arshed A. Quyyumi MD Professor of Medicine Division of Cardiology Emory University School of Medicine

| PowerPoint PPT presentation | free to view

2,6-Xylidine Market Analysis by Production, Revenue, Consumption, Application to 2022 PowerPoint PPT Presentation

2,6-Xylidine Market Analysis by Production, Revenue, Consumption, Application to 2022 - 2,6-Xylidine -Market Competition by Manufacturers,Manufacturers Profiles/Analysis,Manufacturing Cost Analysis,Industrial Chain, Sourcing Strategy and Downstream Buyers,Market Effect Factors Analysis

2,6-Xylidine -Market Competition by Manufacturers,Manufacturers Profiles/Analysis,Manufacturing Cost Analysis,Industrial Chain, Sourcing Strategy and Downstream Buyers,Market Effect Factors Analysis

| PowerPoint PPT presentation | free to download

Congestive Heart Failure Philip D Houck M.D. PowerPoint PPT Presentation

Congestive Heart Failure Philip D Houck M.D. - Title: Congestive Heart Failure Author: car2ph Last modified by: skulesz Created Date: 4/10/2005 1:24:35 PM Document presentation format: On-screen Show (4:3)

Title: Congestive Heart Failure Author: car2ph Last modified by: skulesz Created Date: 4/10/2005 1:24:35 PM Document presentation format: On-screen Show (4:3)

| PowerPoint PPT presentation | free to view

Angina - Symptoms, Causes, and Treatment PowerPoint PPT Presentation

Angina - Symptoms, Causes, and Treatment - While angina is not life-threatening, it can be very uncomfortable and limiting. Learn about the various complication of angina and how to prevent them from happening in the first place.

While angina is not life-threatening, it can be very uncomfortable and limiting. Learn about the various complication of angina and how to prevent them from happening in the first place.

| PowerPoint PPT presentation | free to download

CLINICAL PHARMACOLOGY OF ANTIARRHYTHMIC MEDICATIONS PowerPoint PPT Presentation

CLINICAL PHARMACOLOGY OF ANTIARRHYTHMIC MEDICATIONS - Vincent F. Mauro, PharmD, FCCP Professor of Clinical Pharmacy and Adjunct Professor of Medicine The University of Toledo Prolong QRS Rare SLE Use of Al hydroxide ...

Vincent F. Mauro, PharmD, FCCP Professor of Clinical Pharmacy and Adjunct Professor of Medicine The University of Toledo Prolong QRS Rare SLE Use of Al hydroxide ...

| PowerPoint PPT presentation | free to download

PHL%20313%20 PowerPoint PPT Presentation

PHL%20313%20 - Title: cardiovascular drugs and autacoids Subject: cardiovascular drugs and autacoids Author: ALHARBI Keywords: cardiovascular drugs and autacoids

Title: cardiovascular drugs and autacoids Subject: cardiovascular drugs and autacoids Author: ALHARBI Keywords: cardiovascular drugs and autacoids

| PowerPoint PPT presentation | free to download

Congestive Heart Failure The Road to Recovery Philip D Houck M.D. PowerPoint PPT Presentation

Congestive Heart Failure The Road to Recovery Philip D Houck M.D. - Last Pearl Good is Better The Enemy of Good is Better i.e. -Watermelon Syncope Impella LV Assist Device External Counterpulsation Cardiac Transplantation Ventricular ...

Last Pearl Good is Better The Enemy of Good is Better i.e. -Watermelon Syncope Impella LV Assist Device External Counterpulsation Cardiac Transplantation Ventricular ...

| PowerPoint PPT presentation | free to view

New Anti Arrythmic Drugs For AF PowerPoint PPT Presentation

New Anti Arrythmic Drugs For AF - MASTER ESSAY OF DR MOHAMED MAGED MAHMOUD KHARABISH

MASTER ESSAY OF DR MOHAMED MAGED MAHMOUD KHARABISH

| PowerPoint PPT presentation | free to download

Coronary Heart Disease PowerPoint PPT Presentation

Coronary Heart Disease - ... prasugrel and ticagrelor Approved by SMC Place in therapy not clear May be alternative to clopidogrel as part of dual antiplatelet therapy Some benefits over ...

... prasugrel and ticagrelor Approved by SMC Place in therapy not clear May be alternative to clopidogrel as part of dual antiplatelet therapy Some benefits over ...

| PowerPoint PPT presentation | free to view

PH402 Nitric Oxide and Angina PowerPoint PPT Presentation

PH402 Nitric Oxide and Angina - http://www.americanheart.org/presenter.jhtml?identifier=4472 ... Tadalafil (Cialis) Vardenafil (Levitra) Pharmacokinetics/Side Effects. active orally ...

http://www.americanheart.org/presenter.jhtml?identifier=4472 ... Tadalafil (Cialis) Vardenafil (Levitra) Pharmacokinetics/Side Effects. active orally ...

| PowerPoint PPT presentation | free to view

Coronary%20Heart/Artery%20Disease PowerPoint PPT Presentation

Coronary%20Heart/Artery%20Disease - Coronary Heart/Artery Disease J.B. Handler, M.D. Physician Assistant Program University of New England *

Coronary Heart/Artery Disease J.B. Handler, M.D. Physician Assistant Program University of New England *

| PowerPoint PPT presentation | free to download

New Antithrombotic Agents PowerPoint PPT Presentation

New Antithrombotic Agents - New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University Prophylaxis All three agents effective 220mg dose of dabigatran not ...

New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University Prophylaxis All three agents effective 220mg dose of dabigatran not ...

| PowerPoint PPT presentation | free to view

Diltiazem Drug Interactions: A Quality Assessment of GeneMedRx PowerPoint PPT Presentation

Diltiazem Drug Interactions: A Quality Assessment of GeneMedRx - Objectives for this project Research known pharmacokinetic and pharmacodynamic interactions between ... Pharmacokinetic interaction between tacrolimus and ...

Objectives for this project Research known pharmacokinetic and pharmacodynamic interactions between ... Pharmacokinetic interaction between tacrolimus and ...

| PowerPoint PPT presentation | free to download

Diltiazem Drug Interactions: A Quality Assessment of GeneMedRx - The cyclosporine-sparing effects of diltiazem in renal transplantation. Transplant Proc 1989;21:3955-3957. PMID 2609415. McLachlan AJ & Tett SE.

The cyclosporine-sparing effects of diltiazem in renal transplantation. Transplant Proc 1989;21:3955-3957. PMID 2609415. McLachlan AJ & Tett SE.

| PowerPoint PPT presentation | free to view

Anginal Symptoms: - Anginal Symptoms:

Anginal Symptoms:

| PowerPoint PPT presentation | free to view

Basic Sciences and Clinical Implications for Heart Failure Treatment' PowerPoint PPT Presentation

Basic Sciences and Clinical Implications for Heart Failure Treatment' - OVERTURE. Cytokine antagonists. RENAISSANCE. RECOVER. Endothelin antagonists ... OVERTURE: ACE/NEP Inhibitors. in Heart Failure. Omapatrilat. Enalapril. P=0.187 ...

OVERTURE. Cytokine antagonists. RENAISSANCE. RECOVER. Endothelin antagonists ... OVERTURE: ACE/NEP Inhibitors. in Heart Failure. Omapatrilat. Enalapril. P=0.187 ...

| PowerPoint PPT presentation | free to view

Titledrpauthor: 41BKGersh, B SubdrpJob PowerPoint PPT Presentation

Titledrpauthor: 41BKGersh, B SubdrpJob - Mayo Clinic. 1,228 pt. 3 trials. 2nd generation stents ... Impact of CV Clinical Trials Often Exceeds Conclusions from the Study Results Alone ...

Mayo Clinic. 1,228 pt. 3 trials. 2nd generation stents ... Impact of CV Clinical Trials Often Exceeds Conclusions from the Study Results Alone ...

| PowerPoint PPT presentation | free to view

Angina crnica estable Estraficicacin del riesgo Opciones de tratamiento Modulo: Cardiopata isqumica PowerPoint PPT Presentation

Angina crnica estable Estraficicacin del riesgo Opciones de tratamiento Modulo: Cardiopata isqumica - enfermedad vaso esp stica - disfunci n endotelial- arteritis coronarias- enf de ... No es de 1ra l nea para el diagnostico de dolor tor cico (AHA/ACC) ...

enfermedad vaso esp stica - disfunci n endotelial- arteritis coronarias- enf de ... No es de 1ra l nea para el diagnostico de dolor tor cico (AHA/ACC) ...

| PowerPoint PPT presentation | free to view

Presentacin de PowerPoint PowerPoint PPT Presentation

Presentacin de PowerPoint - Chronic Congestive Heart Failure. Committee on Post Graduate Education, ... Chronic Congestive Heart Failure. The Problem (USA) 5,000,000 patients ...

Chronic Congestive Heart Failure. Committee on Post Graduate Education, ... Chronic Congestive Heart Failure. The Problem (USA) 5,000,000 patients ...

| PowerPoint PPT presentation | free to view

Prim. Mr. Sc. Dr. Nediljko Pivac PowerPoint PPT Presentation

Prim. Mr. Sc. Dr. Nediljko Pivac - KARDIOVASKULARNE BOLESTI Prim. Mr. Sc. Dr. Nediljko Pivac Interna klinika, KBC Split * Treatment of Heart Failure. Angiotensin Converting-Enzyme Inhibitors (ACEI ...

KARDIOVASKULARNE BOLESTI Prim. Mr. Sc. Dr. Nediljko Pivac Interna klinika, KBC Split * Treatment of Heart Failure. Angiotensin Converting-Enzyme Inhibitors (ACEI ...

| PowerPoint PPT presentation | free to view

MERLIN-TIMI 36: Summary and implications PowerPoint PPT Presentation

MERLIN-TIMI 36: Summary and implications - No difference in safety endpoints of all-cause death, all-cause death or CV ... Significant reduction in arrhythmias detected by Holter monitoring during first 7 days ...

No difference in safety endpoints of all-cause death, all-cause death or CV ... Significant reduction in arrhythmias detected by Holter monitoring during first 7 days ...

| PowerPoint PPT presentation | free to view

Ranolazine PowerPoint PPT Presentations